XOMA Royalty Q2 net income $9.2M; acquires Turnstone, HilleVax, LAVA; H1 cash receipts $29.6M

XOMA Royalty Corp

2025-Q2 EPS reported $0.50 revenue$29,041,000

Net income $9.2M (Q2 2025) vs $16.0M (Q2 2024); income & revenue $13.1M vs $11.1M.
H1 2025 cash receipts $29.6M ($16.0M royalties, $13.6M milestones); Q2 cash receipts $11.7M.
Completed Turnstone acquisition (Aug 11); HilleVax expected Sept; LAVA expected Q4 2025.
Deployed $20M for additional mezagitamab royalty; $5M milestone from Rezolute, $3M from Takeda.
Repurchased 107,500 shares in H1 for $2.4M; paid $2.7M in preferred stock dividends.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.